Infección activa o latente que requiere resolución / profilaxis antes de iniciar carbo+pac...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | RF-OVARIAN-INFECTION-SCREENING |
|---|---|
| Tipo | Señal de alerta |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff |
| Enfermedades | DIS-OVARIAN |
| Fuentes | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Origen de la bandera roja
| Definición | Active or latent infection requiring resolution / prophylaxis before initiating carbo+pacli ± bevacizumab and PARPi maintenance in advanced ovarian: HBsAg+ or anti-HBc+ (HBV reactivation on cytotoxic chemo; bevacizumab adds GI / wound-healing complications during reactivation hepatitis), HCV-RNA+, HIV+, active TB, active uncontrolled infection. |
|---|---|
| Dirección clínica | Atención |
| Categoría | detección de infecciones |
| Algoritmo de cambios | ALGO-OVARIAN-ADVANCED-1L |
Lógica de activación
{
"any_of": [
{
"finding": "hbsag",
"value": "positive"
},
{
"finding": "anti_hbc_total",
"value": "positive"
},
{
"finding": "hcv_rna",
"value": "positive"
},
{
"finding": "hiv_status",
"value": "positive"
},
{
"finding": "active_tb",
"value": true
},
{
"finding": "active_uncontrolled_infection",
"value": true
}
],
"type": "composite"
}
Notas
HBsAg+ → entecavir or tenofovir from before first cycle through ≥6 months post-last-chemo / PARPi (PARPi maintenance can be 2-3 years in BRCA+ — extend prophylaxis duration). Bevacizumab during unrecognized HBV reactivation can cause hepatic decompensation and worsen GI mucosal-healing complications (perforation risk). HIV+ with stable ART can receive standard regimens. Active TB: complete intensive-phase anti-TB before initiating chemo. Direction "hold" surfaces a workup-prerequisite annotation rather than switching indication.
Utilizado por
Algoritmos
ALGO-OVARIAN-ADVANCED-1L- ALGO-OVARIAN-ADVANCED-1L